|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
The majority of Type-2 DM patients suffer from visceral obesity and they often have high circulating levels of lipids including cholesterol, triglycerides, low levels of high density cholesterol, which also contribute to the development of vascular complications. In the present investigation the efficacy of Circuma longa extract on serum lipid profile of diabetic mice was studied. The results clearly indicated that Diabetic mice treated with C. longa extract (DT150) the Diabetic mice treated with lower dose of C. longa extract (DT150) showed significantly lower values of serum TC (-26.5%; p<0.001) and TGs (-55.6%; p<0.001), when compared with the DC counterparts. The DT250 treatment showed superior lowering effects compared with the DC counterparts as well as DT150 group mice by (-34.7%; p<0.001) on serum TC levels and (-50%; p<0.001) on TGs levels. Contrarily, treatment with Pioglitazone (DTPGZ) showed (-33.2%; p<0.001) on TC levels and (-09.6%; p<0.001) on TGs levels compared with diabetic control mice. Relative to normal control, the diabetic mice had higher value of low density lipoprotein (LDL) (+256%; p<0.001) while diminished value of high density lipoprotein (HDL) (-55%; p<0.001). Diabetic mice treated with lower dose of Circuma longa extract (DT150) showed significantly lower values of serum LDL (-50%; p<0.001) and higher value of HDL (-45.4%; p<0.001), when compared with the DC counterparts. All over again, the DT250 treatment showed even better lowering effects on LDL (-53%; p<0.001) compared with the DC counterparts and improved level of HDL (+56%; p<0.001). In contrast, treatment with Pioglitazone (DTPGZ) showed a considerable diminished level of LDL (-58%; p<0.001) while improved level of HDL (+59%; p<0.001) compared with diabetic control mice.